The Proteocyte AI Team

An experienced Management team and a world renowned Scientific and Clinical Advisory Board, working together to provide healthcare professionals access to more accurate information and to improve outcomes for patients at risk of cancer.

Proteocyte AI Team

David Mock, DDS, PhD, FRCD(C)

Co-Medical Director

David Mock

David Mock, DDS, PhD, FRCD(C)

Co-Medical Director

Professor Oral Pathology/Oral Medicine, former Dean, Faculty of Dentistry, University of Toronto. Internationally recognized authority in oral pathology.

Kenneth Pritzker, MD, FRCPC, FCAP

Co-Medical Director

Kenneth Pritzker

Kenneth Pritzker, MD, FRCPC

Co-Medical Director

Former Chief of Pathology, Mount Sinai Hospital and currently Professor emeritus, Laboratory Medicine and Pathobiology University of Toronto, Dr. Ken Pritzker is recognized internationally for leadership in laboratory medicine, biomedical research and practical experience bringing new diagnostic tests into practice. Dr. Pritzker has extensive experience introducing innovative companion diagnostics for cancer therapy.

Jason Hwang, PhD

Principal Scientist, Product Development

Jason Hwang

Jason Hwang, PhD

Principal Scientist, Product Development

Dr. Hwang is fluent in the field of cell differentiation/signaling and cancer metastasis, with over seven years of research lab experience and published articles. He has overseen multiple research projects during his graduate work, including the supervision of students and lab members, and is the co-inventor of Proteocyte Diagnostics’ first company patent for the automated method for assessing oral cancer risk progression.
Dr. Hwang obtained his PhD in Developmental Biology from the University of Western Ontario in London, Ontario.

Benjamin J. Dickson, MSc

Manager,

Product Development & Quality Systems

Ben Dickson

Ben Dickson, MSc

Manager, Product Development & Quality Systems

Ben joined Proteocyte AI in January of 2017 following the completion of his Master's degree in Developmental Biology from Western University. Ben's research focused on the role of reactive oxygen species in early development. The project focused on the role of the NADPH oxidase family of proteins, known for their production of reactive oxygen species, in the early developmental process primitive endoderm differentiation.

John R. Jordan, MBA, CPA, CMA

Chief Financial Officer

John R. Jordan

John R. Jordan, MBA, CPA, CMA

Director, Chief Financial Officer

John Jordan has held several positions as CFO including two subsidiaries of US public companies, LandCanada and FNF Canada. In addition, he was the founding CFO of a Canadian financial services technology company that was acquired by Fidelity National Financial, Inc. John started his career in public accounting and has worked with many companies in a variety of industries. With more than 20 years’ experience working with entrepreneurs, John brings a wealth of “hands on” financial and operational experience. He understands what it takes to create and build successful technology businesses. John has a well-rounded business knowledge with specific strengths in start ups, growth and acquisitions strategies, business valuations, and financial management. John is a graduate of Kellogg School of Management, Northwestern University and Schulich School of Business, York University. He is a member of CPA Ontario and the American Institute of Certified Public Accountants. In addition, John holds the AICPA specialty designation of Accredited in Business Valuations (ABV).

Scientific and Clinical Advisors

Anthony Morlandt, MD, DDS, FACS

Assistant Professor

The University of Alabama at Birmingham

Anthony Morlandt

Anthony Morlandt, MD, DDS, FACS

Clinical Advisor

Dr. Morlandt currently serves as Chief of the Section of Oral Oncology within the Department of Oral and Maxillofacial Surgery at University of Alabama at Birmingham (UAB) Medicine and is a full time academic head and neck surgeon. He is Director of the Head and Neck Oncology Fellowship program at UAB. Dr. Morlandt is an Associate Scientist in the Cancer Chemoprevention Program with the UAB Comprehensive Cancer Center. In 2015, Dr. Morlandt received the AAOMS Faculty Educator Development Award and has been inducted into the American Head and Neck Society and is a Fellow of the American College of Surgeons. He is a Diplomate of the American Board of Oral and Maxillofacial Surgery.

Dr. Morlandt was born and raised in Floresville, Texas and graduated from Baylor University. He completed his DDS magna cum laude at the University of Texas Health Sciences Center in San Antonio, Texas, and received his MD and internship and residency in Oral and Maxillofacial Surgery from the University of Alabama School of Medicine. Dr. Morlandt then went on to complete a fellowship in head and neck oncology and microsurgery at the University of Florida College of Medicine in Jacksonville, Florida.

K.W. Michael Siu, PhD, FCIC, FRSC

VP-Research and Innovation

University of Windsor

K.W. Michael Siu

K.W. Michael Siu, PhD, FCIC, FRSC

Co-Inventor & Scientific Advisor

Dr. Siu has extensive experience on administration in academia. He is currently Vice-President, Research and Innovation at the University of Windsor (December 2012 - present). Prior to his current post, Dr. Siu served as Associate Vice-President Research, Science & Technology (2005 - 2011), Founding Director, Centre for Research in Mass Spectrometry (2000 - 2012), and Member, Board of Governors (2004 - 2006) at York University. In addition, he has served and is currently serving in various leadership, administration, and governance positions in Canadian and International Research Organizations, including Chair, Ontario Council on University Research (2017 - 2018), Executive, Board of Directors, Southern Ontario Super Computing Innovation Platform (SOSCIP; 2016 - present), President, Canadian Society for Mass Spectrometry (2009 - 2012), Chair, Board of Directors, Canadian National Proteomics Network (2008 - 2012), and Member, Board of Directors, Human Proteome Organization (2010 - 2012).

His academic experience and accomplishments are also extensive. He is currently Professor of Chemistry and Biochemistry at the University of Windsor. At York University, he was Distinguished Research Professor (2007 - 2014) and NSERC/AB SCIEX Senior Industrial Research Chair in Analytical Mass Spectrometry (1998 - 2012). Dr. Siu has published over 270 papers (Google Scholar, August 17, 2018: h-index: 60; i10-index: 211; total citations: 11,443; papers cited more than 100 times: 27) and given over 480 presentations, of which more than 50% are in the invited, keynote, and plenary category. He is a Fellow of the Chemical Institute of Canada and the Royal Society of Canada. Dr. Siu has received multiple awards, as well as funding and grants from many agencies and organizations totalling over $22 million.

Ranju Ralhan, PhD, FNAMS

Professor

Otolaryngology-Head & Neck Surgery

University of Toronto

Ranju Ralhan

Ranju Ralhan, PhD, FNAMS

Co-Inventor & Scientific Advisor

Dr. Ranju Ralhan is a Professor, Department of Otolaryngology-Head & Neck Surgery, University of Toronto, Director, Alex and Simona Shnaider Laboratory of Molecular Oncology, Director of Research and Senior Scientist, Joseph and Mildred Sonshine Family Centre for Head & Neck Diseases, Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Hospital. Dr. Ralhan has been awarded the prestigious CIHR Rx & D Research Chair to advance the development of cancer biomarkers. Dr. Ralhan is an internationally recognized pioneer in cancer biology, proteomics, genomics, epigenomics, molecular diagnostics, molecular targeted therapy, cancer stem cells, and translational research. Dr. Ralhan’s translational research laboratory has made numerous contributions to the understanding of basic mechanisms of head and neck, esophageal and breast carcinogenesis, which have led to discovery of novel predictive, diagnostic and prognostic cancer markers and identified new targets for molecular therapy. Dr. Ralhan has received numerous international awards for her work on cancer biomarkers and drug targets.
Dr. Ralhan received her PhD in Medical Biochemistry from University of Delhi, India and was awarded the Fogarty Post-Doctoral Fellowship of National Cancer Institute, National Institutes of Health, MD, US.

Barrie M. Renick, BSc, DDS, Dip Oral Path, Dip Oral Surgery, MRDC(C)

Oral and Maxillofacial Surgeon

Barrie Renick

Barrie Renick, BSc, DDS, Dip Oral Path, Dip Oral Surg, MRDC(C)

Clinical Advisor

Dr. Renick has a broad-based Oral Surgery practice with an interest in oral disease, cysts, and tumors. He has been in private practice in Newmarket and a Staff surgeon at Southlake Hospital for over 25 years. During this time, he has provided general anesthesia to more than 15,000 patients.

Dr. Renick is the only dentist in Canada with dual specialty training in both Oral Surgery and Oral Pathology. His training includes experience at Toronto General, Toronto Western Hospital, The Wellesley Hospital, Sick Kids, Sunnybrook Hospital, Odette Cancer Clinic, Princess Margaret Hospital, and The Sunnybrook Interdisciplinary Mouth Clinic.

Mark Nusinoff, BSc, DDS, FADI, FICD

Dentist

Mark Nusinoff

Mark Nusinoff, BSc, DDS, FADI, FICD

Clinical Advisor

Dr. Nusinoff brings over 30 years of clinical experience. He is the principal dentist of Yonge Street Dental, a successful dental practice in midtown Toronto. He is an active member in many dental societies and holds fellowships in the International College of Dentists, the Academy of Dentistry International and Pierre Fauchard Academy. He is also a member of the Omicron Kappa Upsilon honour dental society. He is a member and past president of the George Hare Endodontic Study club and a 35 year member of the Toronto Crown and Bridge study club. He has been a member of the ODA/CDA and RCDS for over 35 years.

Ian Witterick, MD, MSc, FRCSC

Chief, Professor and Chair

Otolaryngology-Head & Neck Surgery

Mount Sinai Hospital and University of Toronto

Ian Witterick

Ian Witterick, MD, MSc, FRCSC

Dr. Witterick is the Otolaryngologist-in-Chief, Sinai Health Systems and the Chief of the Department of Otolaryngology - Head & Neck Surgery at Mount Sinai Hospital. He is a Professor and Chair of the Department of Otolaryngology - Head & Neck Surgery at the University of Toronto. He is a Diplomat of the American Board of Otolaryngology and a Fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Witterick is a highly regarded teacher, receiving various teaching awards including the Postgraduate Medical Education Program Development and Innovation Award and the Charles Mickle Fellowship Award. He has received the Educational Excellence Award from the Canadian Society of Otolaryngology - Head & Neck Surgery and a presidential citation from the American Head & Neck Society.